Acute respiratory distress syndrome: potential of therapeutic interventions effective in treating progression from COVID-19 to treat progression from other illnesses—a …

EJ Ragel, LK Harris… - BMJ Open Respiratory …, 2023 - bmjopenrespres.bmj.com
Background Acute respiratory distress syndrome (ARDS) is the most severe form of lung
injury, rendering gaseous exchange insufficient, leading to respiratory failure. Despite over …

[HTML][HTML] Pharmacological management of COVID-19 patients with ARDS (CARDS): a narrative review

MG Matera, P Rogliani, L Calzetta, M Cazzola - Respiratory medicine, 2020 - Elsevier
Abstract Coronavirus disease 2019 (COVID-19) is highly infectious. It has been highlighted
that if not expertly and individually managed with consideration of the vasocentric features, a …

COVID-19-Associated acute respiratory distress syndrome (CARDS): Mechanistic insights on therapeutic intervention and emerging trends

K Thapa, N Verma, TG Singh, AK Grewal… - International …, 2021 - Elsevier
Abstract Aims The novel Coronavirus disease 2019 (COVID-19) has caused great distress
worldwide. Acute respiratory distress syndrome (ARDS) is well familiar but when it happens …

[HTML][HTML] A narrative review of COVID-19-related acute respiratory distress syndrome (CARDS):“typical” or “atypical” ARDS?

D Pu, X Zhai, Y Zhou, Y Xie, L Tang, L Yin… - Annals of translational …, 2022 - ncbi.nlm.nih.gov
Methods We searched for relevant literature from 1999 to 2021 published in PubMed by
using the following keywords and their combinations:“COVID-19”,“CARDS”,“ARDS”,“ …

[HTML][HTML] COVID-19-associated acute respiratory distress syndrome (CARDS): Current knowledge on pathophysiology and ICU treatment–A narrative review

CA Pfortmueller, T Spinetti, RD Urman… - Best Practice & …, 2021 - Elsevier
Abstract (163 words) Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
induces coronavirus-19 disease (COVID-19) and is a major health concern. Following two …

[HTML][HTML] Acute respiratory distress syndrome and the use of inhaled pulmonary vasodilators in the COVID-19 era: a narrative review

A Nasrullah, S Virk, A Shah, M Jacobs, A Hamza… - Life, 2022 - mdpi.com
The Coronavirus disease (COVID-19) pandemic of 2019 has resulted in significant morbidity
and mortality, especially from severe acute respiratory distress syndrome (ARDS). As of …

[HTML][HTML] Emerging pharmacological therapies for ARDS: COVID-19 and beyond

S Horie, B McNicholas, E Rezoagli, T Pham… - Intensive care …, 2020 - Springer
ARDS, first described in 1967, is the commonest form of acute severe hypoxemic respiratory
failure. Despite considerable advances in our knowledge regarding the pathophysiology of …

[PDF][PDF] Rapid progression to acute respiratory distress syndrome: Review of current understanding of critical illness from coronavirus disease 2019 (COVID-19) …

KJ Goh, MC Choong, EHT Cheong… - Ann Acad Med …, 2020 - annals.edu.sg
The outbreak of coronavirus disease 2019 (COVID-19) in December 2019 in the city of
Wuhan in Mainland China has spread across the globe with> 100,000 infected individuals …

[HTML][HTML] A systematic review of cases of acute respiratory distress syndrome in the coronavirus disease 2019 pandemic

M Baksh, V Ravat, A Zaidi, RS Patel - Cureus, 2020 - ncbi.nlm.nih.gov
The outbreak of coronavirus disease 2019 (COVID-19) was declared a global pandemic
after it spread to 213 countries and has the highest total number of cases worldwide. About …

Acute respiratory distress syndrome

K Powers - JAAPA, 2022 - journals.lww.com
Acute respiratory distress syndrome (ARDS) is a severe, often fatal, lung condition frequently
seen in patients in the ICU. ARDS is triggered by an inciting event such as pneumonia or …